Catena Biosciences
S21
Active

Catena Biosciences

Using protein coupling to cure autoimmune disorders.

Catena’s technology lets us attach any two proteins together using an enzyme -tyrosinase- and the native amino acids tyrosine and cysteine within target proteins. It is a true platform technology because it enables the joining of any two soluble proteins together with minimal engineering and without restrictions due to protein size or complexity. Our work has already been used to modify cancer specific antibodies, but the most exciting application is in the emerging field of immune tolerance induction. Catena’s technology allows us to couple receptor binding proteins to immune triggering partners, letting us retrain the immune system when it targets healthy proteins. Such treatments could effectively cure autoimmune diseases such as Multiple Sclerosis, Graves' Disease and Hashimoto's by limiting inflammation towards ankyrin, anoctamin, and other self-antigens.

Geo Guillen

Geo Guillen​ is Co-Founder and COO of Catena Biosciences. Geo is an MBA graduate from the Haas School of Business with years of experience working at some of the largest tech companies in the world. Companies such as Facebook, Google, and Microsoft in Product Management, Product Marketing, Sales, and Operations. Geo has made it his passion to further develop technologies in this space to help those suffering from autoimmune disorders as he has been personally affected by this issue.

Marco Lobba

CEO and Co-Founder at Catena Biosciences. Marco completed his Ph.D. at UC Berkeley jointly between the labs of Matt Francis and Jennifer Doudna. When not starting a company or doing science Marco likes to backpack, rock climb, kayak, and just about any activity that involves not being inside.

Matthew Francis

Matthew Francis
Matthew Francis
Catena Biosciences